This clinical trial is focused on studying treatments for Relapsed or Refractory Multiple Myeloma, a type of blood cancer that has returned or is not responding to previous treatments. The study will explore different combinations of medications to find the most effective treatment. The medications being tested include Talquetamab, Pomalidomide, Teclistamab, Elotuzumab, Bortezomib, and Dexamethasone. Some of these medications are given as tablets or capsules, while others are administered through injections.
The purpose of the study is to compare the effectiveness of these medication combinations. Participants will be randomly assigned to receive one of the following treatments: Talquetamab with Pomalidomide, Talquetamab with Teclistamab, or a combination chosen by the investigator, which could be Elotuzumab, Pomalidomide, and Dexamethasone, or Pomalidomide, Bortezomib, and Dexamethasone. Some participants may receive a placebo. The study will last for a period of up to 24 months, during which participants will receive regular treatments and check-ups to monitor their health and the progress of the disease.
Throughout the study, the main focus will be on measuring how long participants live without the disease getting worse, known as progression-free survival. This will help researchers understand which treatment combination works best for patients with relapsed or refractory multiple myeloma. Participants will be closely monitored by healthcare professionals to ensure their safety and well-being during the trial.



Austria
Belgium
Czechia
Denmark
France
Germany
Greece
Hungary
Italy
Poland
Spain
Sweden
The Netherlands